Stockcharts @ TTNP

Solid gains today +3.33% or +.19 with key indicators moving up!



Investor 100

Worth Repeating Last PR@IMNP

Buying Opportunity based on last PR!

https://finance.yahoo.com/news/immune-pharmaceuticals-receives-2-million-113000884.html

Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share

NEW YORK, Sept. 7, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) ("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that it has entered into a stock purchase agreement with an existing stockholder for the sale of 4,000,000 shares of the Company's common stock at a fixed price of $0.50 per share, for gross proceeds of $2,000,000. There are no warrants, no restrictive covenants, and no restrictions on use of proceeds.

Investor 100

A lack of patience among traders!

Some see the glass half empty others half full.

Investor 100

Starter Position @ VCEL

With the dip I took a position today.

GL

Investor 100

Immune Pharmaceuticals Signs Agreement to Fund Maxim Pharmaceuticals, Inc., its Pain and Neurology subsidiary

http://finance.yahoo.com/news/immune-pharmaceuticals-signs-agreement-fund-113000775.html

NEW YORK, Sept. 16, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) ("Immune" or the "Company"), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that the Board of Directors has approved to designate Maxim Pharmaceuticals Inc. ("Maxim"), one of the Company's existing subsidiaries, as the dedicated entity to develop and commercialize, and hold the intellectual property related to, AmiKet® and other related pain and neurology assets. In addition, the Company has entered into a binding agreement with NPT (the "Binding Agreement"), a syndicate of experienced healthcare investors, pursuant to which NPT or its designees have agreed to purchase up to $20 million of the capital stock of Maxim, with an initial funding of $5 million to occur within thirty days. Previously, the Company entered into an option agreement with NPT, dated May 15, 2016, as amended on July 18, 2016. Pursuant to the Binding Agreement, immediately following the $5 million initial funding by NPT, Immune will expand the Board of Directors of Maxim, to five members which will include one NPT representative, and a newly hired Chief Executive Officer of Maxim.

For full disclosure please refer to the Form 8-K filed on September 16, 2016

About Immune Pharmaceuticals Inc.:
Immune Pharmaceuticals Inc. (IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in Phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and Non-Alcoholic Steato-Hepatitis (NASH), an inflammatory liver disease. Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's oncology pipeline includes Ceplene®/IL-2 approved in Europe and Israel for maintenance remission in Acute Myeloid Leukemia (AML), Azixa® and crolibulin, Phase II-ready vascular disrupting agents, and novel technology platforms; bispecific antibodies and targeted nanotherapeutics, NanomAbs™. Immune's additional pipeline includes AmiKet™ Nano, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharma.com, the content of which is not a part of this press release.

Investor 100

VCEL @ Stockcharts

Like this opportunity heading into the 4th quarter and indicators RSI/MACD/MFI heading upward...more room to run!

Pipeline:
http://vcel.com/research-and-development/#PipelineSection



Investor 100

ReviewFortune @ IMNP

Nice write up @ IMNP

http://reviewfortune.com/2016/09/07/the-insider-activity-dont-lie-immune-pharmaceuticals-inc-nasdaqimnp-3/

Investor 100

Marketwatch @ IMNP

More exposure for IMNP

http://www.marketwatch.com/story/research-reports-coverage-on-healthcare-stocks----immune-pharma-sanofi-shire-and-universal-health-services-2016-09-09

Immune Pharma

New York headquartered Immune Pharmaceuticals Inc.'s stock finished Thursday's session 2.70% lower at $0.36. A total volume of 3.10 million shares was traded, which was above their three months average volume of 2.72 million shares. The Company's shares are trading below their 50-day moving average by 8.26%. Furthermore, shares of Immune Pharmaceuticals, which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, have a Relative Strength Index (RSI) of 45.66.

On September 7 [th] , 2016, Immune Pharmaceuticals announced that it has entered into a stock purchase agreement with an existing stockholder for the sale of 4,000,000 shares of its common stock at a fixed price of $0.50 per share, for gross proceeds of $2,000,000. The company noted that there are no warrants, no restrictive covenants, and no restrictions on use of proceeds. Your complete research report on IMNP can be retrieved for free at:

http://stock-callers.com/registration/?symbol=IMNP


Investor 100

IPCI @ Stockcharts

Strong indicators with MFI,MACD and RSI..solid movement upwards!



Investor 100

IMNP@ Stockcharts

No question some buying opportunities the past few weeks!




Investor 100

Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share

Nice to see a bump in the PPS this morning!

https://finance.yahoo.com/news/immune-pharmaceuticals-receives-2-million-113000884.html

NEW YORK, Sept. 7, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) ("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that it has entered into a stock purchase agreement with an existing stockholder for the sale of 4,000,000 shares of the Company's common stock at a fixed price of $0.50 per share, for gross proceeds of $2,000,000. There are no warrants, no restrictive covenants, and no restrictions on use of proceeds.

For full disclosure, please refer to the Form 8-K filed on September 7, 2016.

Investor 100

TPIV @ Stockcharts

Nice upward movement..RSI..MACD and MFI..up 4.70%!



Investor 100

IMNP @ Stockcharts

No question a buying opportunity of late at IMNP!

Last 30 day
CEO of Immune Pharmaceuticals Inc (IMNP) Daniel Gedeon Teper bought 937,500 shares of IMNP on 08/04/2016 at an average price of $0.38 a share. The total cost of this purchase was $356,250.

Immune Pharmaceuticals Inc is a clinical stage biopharmaceutical company specializing in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer. Immune Pharmaceuticals Inc has a market cap of $13.513 million; its shares were traded at around $0.33 .

http://finance.yahoo.com/news/immune-pharmaceuticals-inc-imnp-ceo-061503523.html;_ylt=A0LEV1IS6slXbe4AiGJXNyoA;_ylu=X3oDMTEyNzYzdHA4BGNvbG8DYmYxBHBvcwM2BHZ0aWQDQjE3OTNfMQRzZWMDc3I-



Investor 100

IMNP @ Stockcharts

Some terrific buying opportunities for those that wanted to get onboard as well as those that wanted to add more shares.

Management shares purchased has been at much higher prices!

http://openinsider.com/search?q=imnp




Investor 100

Stockcharts @ TTNP

Like all three indicators RSI, MACD and MFI and passed the 50 (MA)



Investor 100

DD @ SCYX

Solid DD from IHUB board member KEI:

(has first catalyst in 3Q)
http://investorshub.advfn.com/uimage/uploads/2016/8/8/uuqelimage.jpg

and beyond:
http://investorshub.advfn.com/uimage/uploads/2016/8/17/[fuhzimage.jpg

in this graph, tute(s) owns 61%, but imo, based on the insane volume on wednesday and thursday, a lot more tute buys will be reported.
http://www.nasdaq.com/symbol/scyx/ownership-summary

i bought my SCYX at $2.02 without knowing Baker Bros, James Flynn, Kevin Kotler all added significant shares here. and i, of course, added more at $2.48.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124384458&txt2find=scyx

you see big names here:
http://investorshub.advfn.com/uimage/uploads/2016/8/18/bjowiimage.jpg

a lot of insider buys also in 2Q (officers and directors bought shares here 'direct')
http://www.nasdaq.com/symbol/scyx/insider-trades
as we know, insiders know their company best.

initiated with a Buy at Guggenheim - PT $15

i wrote here blah blah blah ...but this is a biotech and we have to take risk(s).
with that said, risk/reward ratio looks great to me.

IMUC @ Stockcharts

It is a lotto play but I like ther odds we move much higher..MFI and MACD moving up!



Investor

Presentations @ IMUC

8k out today..bought a bunch...closed at .13 or +5.8% with 9M+ shares traded...moving higher IMHO.

http://investors.imuc.com/events.cfm

Investor 100

SCYX @ Stockcharts

Solid MOM run today with RSI,MACD and MFI heading higher...going much higher...bought a bunch today!

Needham's PT is $16

http://investorshub.advfn.com/uimage/uploads/2016/7/11/okpwgimage.jpg



Investor 100

Institutional Holders @ SCYX

58.90% shares owned by institutions...some strong players..Baker ..Deerfield...FMR...

https://finance.yahoo.com/quote/SCYX/holders?p=SCYX


Investor 100

SCYX @ Stockcharts

Some strong buying this past week with all indicators...RSI..MFI...MACD looking to go higher!

Have a small position but will add on any dip.



Investor 100

IMNP @ Stockcharts

Strong Friday with over 3.1M shares traded, closing .40 or +7.53% with RSI and MFI moving upward...added on the dips this week!




Investor 100

Analyst Ratings for Immune Pharmaceuticals (IMNP)

http://www.streetinsider.com/rating_history.php?q=IMNP


Investor 100

Immune Pharmaceuticals’ (IMNP) “Buy” Rating Reaffirmed at FBR & Co

Interesting assessment of IMNP

http://www.americanbankingnews.com/2016/08/18/immune-pharmaceuticals-imnp-buy-rating-reaffirmed-at-fbr-co/


Investor 100

IMUC @ Stockcharts

Took a big haircut with its offering but I think we are slowly turning a bit upward as the chart begins it slow ascend with MACD and MFI trending upward!




Investor 100

Delving Deep into Immune Pharmaceuticals' Diverse Pipeline IMNP

Excellent / In-Depth article a must read to fully understand the opportunity at IMNP!

https://www.streetwisereports.com/pub/na/delving-deep-into-immune-pharmaceuticals-diverse-pipeline

Investor 100

IMNP @ Stockcharts

Lots of opportunity to start or add a position the past few days!



Investor 100

AH @ IMNP

77k shares traded closing at .43.


Investor 100

Stockcharts @ IMUC

Took a 32% haircut todat closing at .13 with 14M shares traded...had a small starter and added a much larger position given ZI like the storyline and the cheap shares making this a lotto play!



Investor 100

Stockcharts @ IMNP

What a day over 10M shares traded, -20% closing at .38..any coincidence that is what CEO D.Tepper paid almost a million shares!

I suspect many sold shares however I doubled up my position on this dip as this storyline has not changed!



Investor 100

Stats @ IMNP

http://www.nasdaq.com/symbol/imnp/insider-trades

Investor 100

Final Bell Chart @ IMNP

Lots of MOMO on this play as the RSI,MACD and MFI are heating up and moving higher with a 29.63% gainer with almost 10M shares traded!



Investor 100

Stockcharts @ IMNP

Late afternoon chart continues to show strength on RSI,MACD, and MFI... up 26% with over 8.5M shares traded!

10 minutes to trade!



Investor 100

Stockcharts @ IMUC

Key indicators moving up RSI,MACD,MFI...took a position today!

Bottom is in at .18-.19.



Investor 100

Stockcharts @ IMNP

Mid-Day chart looks solid as key indicators moving higher ...RSI..MACD and MFI..up 26% over 7M shares traded!




Investor 100

Stockcharts @ IMNP

All three key indicators looking good , RSI,MACD and MFI!

Form 4: CEO D.Tepper owns over 5.7M shares!

https://www.sec.gov/Archives/edgar/data/1208261/000114420416116711/xslF345X03/v446157_4.xml



Investor 100

Form 4 @ IMNP

CEO D tepper holding a boat load of shares-talk about confidence!

https://www.sec.gov/Archives/edgar/data/1208261/000114420416116711/xslF345X03/v446157_4.xml

Investor 100

Stay On Topic @ IMNP

Please post on IMNP given that is the topic.

Thanks,

Investor 100

Immune Pharmaceuticals, Inc. @ 2nd IOBDLI Forum

CEO D. Tepper speaking jyst a few months back June 2016.

ImmunoCellular Therapeutics Reports Progress in Two Lead Cancer Immunotherapy Programs
Over 100 Patients Screened in Phase 3 ICT-107 Trial in Newly Diagnosed Glioblastoma;
CIRM Award Payment of $1.5 Million Received;
ICT-121 Phase 1 Trial in Recurrent Glioblastoma Fully Enrolled

http://investors.imuc.com/releasedetail.cfm?ReleaseID=980859

http://clinicaltrials.pharmaceutical-business-review.com/news/immunocellular-secures-grant-for-clinical-trial-of-glioblastoma-250915-4678611

LOS ANGELES, July 25, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today reported progress in its two lead cancer immunotherapy clinical programs: the phase 3 registrational trial of ICT-107 for newly diagnosed glioblastoma and the phase 1 trial of ICT-121 for recurrent glioblastoma.

As previously disclosed, in September of 2015, The California Institute of Regenerative Medicine (CIRM) awarded ImmunoCellular up to $19.9 million toward financing the ICT-107 phase 3 trial. This award is distributed to ImmunoCellular in milestone payments that are primarily dependent on patient enrollment and randomization. In June 2016, ImmunoCellular amended the terms of its award from CIRM to (i) increase the project initial payment by $1.5 million, and (ii) reduce the potential future milestone payments by a corresponding $1.5 million. The potential total amount of the award from CIRM remains at $19.9 million, inclusive of amounts received to date. On July 18, 2016, ImmunoCellular received the $1.5 million payment from CIRM related to the increase in the project initial payment. To date, ImmunoCellular has received $5.5 million from CIRM.

Investor 100